NCT01837797View on ClinicalTrials.gov

Efficacy and Safety of Brexpiprazole as Adjunctive Treatment in Elderly Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment

PHASE3TerminatedINTERVENTIONAL
Enrollment

129

Participants

Timeline

Start Date

April 30, 2013

Primary Completion Date

May 31, 2014

Study Completion Date

May 31, 2014

Conditions
Major Depressive Disorder
Interventions
DRUG

Placebo

Once daily, tablets, orally

DRUG

Brexpiprazole 1 mg

once daily dose, tablets, orally

DRUG

Brexpiprazole 3 mg

once daily dose, tablets, orally

Trial Locations (2)

32806

US008, Orlando

91950

US001, National City

Sponsors
All Listed Sponsors
collaborator

Otsuka Pharmaceutical Co., Ltd.

INDUSTRY

lead

H. Lundbeck A/S

INDUSTRY